SynthesisNeurosurgical review2026
Risk of post-revascularization stroke in Moyamoya disease: A systematic review, meta-analysis, and meta-regression.
Synthesis in Neurosurgical review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease is a progressive cerebrovascular disorder in which cerebral revascularization is the primary treatment, yet post-revascularization stroke remains a serious and inconsistently reported complication. This meta-analysis was therefore undertaken to quantify the risk of post-revascularization stroke and identify phenotype-specific predictors with the ultimate goal of informing perioperative decision making in order to improve surgical outcomes in patients with moyamoya disease. A comprehensive literature search of databases was performed through October 2025, in accordance with PRISMA guidelines and prospectively registered (CRD420251108075). Pooled odds ratios (ORs) were estimated using a restricted maximum likelihood random-effects model, with heterogeneity quantified by I². Meta‐regression was applied to explore study‐level moderators. Twenty-six studies involving 9,698 patients (mean age 40.16 ± 2.02 years; 63.57% female) met the inclusion criteria. Age (per year increase) (OR: 1.02; 1.02–1.03), diabetes mellitus (OR: 1.35; 1.15–1.58), hypertension (OR: 1.05; 1.00–1.10), smoking (OR: 1.84; 1.22–2.77), PCA involvement (OR: 2.22; 1.55–3.17), presenting ischemia (OR: 2.54; 1.54–4.16), and advanced Suzuki grade (OR: 1.20; 1.01–1.42) were associated with increased post-revascularization stroke risk. Surgical intervention reduced the risk of stroke (OR: 0.66; 0.45–0.97). In ischemic moyamoya disease, thyroid disorder, smoking, diabetes mellitus, PCA involvement, advanced Suzuki grade, and increasing age merged as the principal predictors of any post-revascularization stroke. In hemorrhagic moyamoya disease, the risk of post-revascularization stroke was more strongly associated with diabetes mellitus and increasing age. Meta-regression analyses indicated variable influence of clinical and procedural factors. Advanced age, vascular risk factors (diabetes mellitus, hypertension, and smoking), radiographic disease severity (PCA involvement and advanced Suzuki grade), and ischemic presentation were associated with an increased risk of post-revascularization stroke in moyamoya disease, with distinct predictor profiles observed across ischemic and hemorrhagic phenotypes. Revascularization was associated with a lower overall stroke risk, supporting its therapeutic benefit.
Indexed as
Identifiers
41888499What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.